Laursen L C, Johannesson N, Dirksen A, Djurup R, Munch E P, Taudorf E, Weeke B
Allergy. 1983 Jan;38(1):75-9. doi: 10.1111/j.1398-9995.1983.tb00859.x.
The bronchodilating effect of two doses of peroral enprofylline was compared with placebo in 24 asthmatic patients. Enprofylline produced significantly greater bronchodilatation than placebo. A dose of 2 mg/kg b.wt. and 4 mg/kg b.wt. caused a mean maximal increase in FEV1 of 26% and 35%, respectively. The degree and the incidence of headache and nausea were estimated by means of a scoring system. Dose-related effects on both parameters were observed. Other side effects were negligible. In seven patients the mean plasma half-life of enprofylline was found to be 113 min. It is suggested that enprofylline should be studied further in patients suffering from obstructive lung disease.
在24名哮喘患者中，比较了两剂口服恩丙茶碱与安慰剂的支气管扩张作用。恩丙茶碱产生的支气管扩张作用明显大于安慰剂。2毫克/千克体重和4毫克/千克体重的剂量分别使第一秒用力呼气量（FEV1）平均最大增加26%和35%。通过评分系统评估头痛和恶心的程度及发生率。观察到这两个参数存在剂量相关效应。其他副作用可忽略不计。在7名患者中，发现恩丙茶碱的平均血浆半衰期为113分钟。建议对患有阻塞性肺病的患者进一步研究恩丙茶碱。
